The Challenge of immune-Cold Tumors

Malignant tumors are often described as immune-suppressive, or “immune cold,” meaning the patient’s immune system fails to recognize or attack them. Patients with these tumors typically experience poorer responses to conventional therapies and face worse prognoses. This study, published in Nature Immunology, explores a novel approach to convert these immune-cold tumors into immune-responsive, or “immune hot” tumors, enabling immune cells like B cells and T cells to more effectively target and destroy cancer cells, and enhancing the success of chemotherapy and immunotherapy.

How Tertiary Lymphoid Structures (TLS) Play a Role

The research builds upon previous work in breast cancer, leading the team to hypothesize that enhancing the tumor environment with immune-activating agents could improve the “fitness” of tertiary lymphoid structures (TLSs) and dramatically boost immune responses against tumors.

TLSs are clusters of lymphocytes that form in areas of chronic inflammation, including immune-hot tumors.These structures are crucial for the immune system’s ability to fight cancer, and their presence is strongly correlated with improved treatment responses and patient survival.

The Experimental Approach: Reverse-Engineering TLS Formation

To understand how to stimulate TLS formation, the researchers “reverse-engineered” a TLS-rich tumor environment to identify the necessary stimuli. They then applied these stimuli to tumors lacking TLS in mice,administering two immune-activating substances – agonists that stimulate the protein STING and the lymphotoxin-β receptor (LTβR).

Dual activation of STING and LTβR triggered a rapid response from killer T cells (CD8⁺ T cells), leading to significant tumor growth inhibition. The treatment also induced the formation of high endothelial venules (HEVs), which are specialized blood vessels that facilitate the entry of immune cells into the tumor.

Key Findings and Implications

The study demonstrates that manipulating the tumor microenvironment to promote TLS formation can effectively convert immune-cold tumors into immune-hot tumors, leading to improved anti-tumor immunity and survival in mouse models of breast, pancreatic, and muscle cancers.

This research, federally funded by the National Cancer Institute/NIH, suggests a promising new avenue for cancer treatment. By “spicing up” the tumor environment,it may be possible to unlock the power of the immune system to fight cancer more effectively.

Expert Analysis